News | August 21, 2008

St. Jude Medical Gets FDA Approval of Arecibo Manufacturing Plant

August 22, 2008 - St. Jude Medical Inc. this week said the FDA approved of the company’s new facility in Arecibo, Puerto Rico, for the manufacturing of pacemakers and cardiac leads.

The 150,000 square-foot facility, located in Arecibo’s Santana Industrial Park, will initially be used to produce St Jude Medical pacemakers and cardiac leads for domestic and international markets, and the company plans to begin manufacturing implantable cardioverter defibrillators (ICDs) at the facility late this year. The new plant will expand the company’s cardiac rhythm management manufacturing capacity and is expected to create at least 1,250 new jobs within the next three years.

The approval followed a six-month review that included an on-site evaluation by FDA inspectors.

The expansion in Puerto Rico follows other recent expansions at two St. Jude Medical manufacturing facilities in Sylmar, CA., and Liberty, SC, as well as the ongoing expansion at the company’s global headquarters in St. Paul, MN.

In 1987, St. Jude Medical began operations in Puerto Rico with 25 employees at its current Caguas facility. The original 23,000 square-foot plant, which manufactured mechanical heart valves, has evolved with the company’s continuous development of new cardiovascular products, tripling its size and expanding its scope to manufacture more than 220 models of cardiovascular and cardiac rhythm management products that are exported to countries around the world.

The Caguas site will continue to manufacture mechanical heart valves and Angio-Seal vascular closure devices, and also is expected to add new product lines in the future.

For more information: www.sjm.com

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init